Efficacy and safety of recombinant von Willebrand factor in on-demand treatment of children with von Willebrand disease: up to 4 years of phase 3/3b follow-up
Shayla Bergmann, Sanjay Ahuja, Canan Albayrak, Marjon H. Cnossen, Amy L. Dunn, Veerle Labarque, Matteo Luciani, Christoph Male, Eric S. Mullins, Sophie Susen, Pascual Marco Vera, Ali G. Mokdad, Yi Wang, Josh Weng, and Jingmei Zhang
4 sections · about 32 minutes · source text with editorial apparatus kept separate